Just five months after raising about $94.8 million in a well-received initial public offering (IPO), Auspex Pharmaceuticals Inc. has priced a new follow-on offering expected to raise an additional $60.6 million to carry a new pivotal trial of its lead candidate, SD-809 (dutetrabenazine), in the movement disorder tardive dyskinesia and to support the company through at least the second quarter of 2016.